These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775 [TBL] [Abstract][Full Text] [Related]
4. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394 [TBL] [Abstract][Full Text] [Related]
5. The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. Stone NJ; Grundy SM Prog Cardiovasc Dis; 2019; 62(5):375-383. PubMed ID: 31733217 [TBL] [Abstract][Full Text] [Related]
6. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572 [TBL] [Abstract][Full Text] [Related]
7. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan. Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405 [TBL] [Abstract][Full Text] [Related]
9. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300 [TBL] [Abstract][Full Text] [Related]
11. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Duprez DA; Handelsman Y; Koren M Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551 [TBL] [Abstract][Full Text] [Related]
13. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. Adhyaru BB; Jacobson TA Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517 [TBL] [Abstract][Full Text] [Related]
14. Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. Wong ND; Amsterdam EA; Ballantyne C; Khera A; Nasir K; Toth PP; Am J Cardiovasc Drugs; 2020 Feb; 20(1):1-9. PubMed ID: 31286451 [TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712 [TBL] [Abstract][Full Text] [Related]
17. Nonstatin therapies for management of dyslipidemia: a review. Sando KR; Knight M Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799 [TBL] [Abstract][Full Text] [Related]
18. Lipid management in ACS: Should we go lower faster? Gencer B; Mach F Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301 [TBL] [Abstract][Full Text] [Related]
19. Implications for REDUCE IT in clinical practice. Bittner V Prog Cardiovasc Dis; 2019; 62(5):395-400. PubMed ID: 31715195 [TBL] [Abstract][Full Text] [Related]
20. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease. Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]